Profile
| Metric | Value |
|---|---|
| Full Name | Relay Therapeutics, Inc. |
| Ticker | NASDAQ: RLAY |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | relaytx.com |
| Employees | 259 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $8.18 | |
| Price, 1D Change | +0.12% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.76 | |
| Revenue | $10M | |
| Revenue, 1Y Change | -60.83% | |
| EPS | -$2.36 | |
| EPS, 1Y Change | +15.27% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.36 | |
| EPS Estimate | -$1.74 | |
| EPS Est. Change | +26.28% | |
| Revenue | $10.01M | |
| Revenue Estimate | $12.77M | |
| Revenue Est. Change | +27.63% | |
| Current Price | $8.18 | |
| Price Target | - | $14.50 |
| Price Tgt. Change | - | +77.26% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.88 | -$2.79 | +3.13% | |
| -$2.47 | -$2.36 | +4.28% | |
| -$1.74 | N/A | +26.28% | |
| -$1.61 | N/A | +32.06% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $25.74M | $25.55M | -0.75% | |
| $15.08M | $10.01M | -33.63% | |
| $12.77M | N/A | +27.63% | |
| $13.26M | N/A | +32.52% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +77.06% | |
| Price, 3Y | -48.03% | |
| Market Cap, 1Y | +82.93% | |
| Market Cap, 3Y | -25.63% | |
| Revenue, 1Y | -60.83% | |
| Revenue, 3Y | +230.37% | |
| EPS, 1Y | +15.27% | |
| EPS, 3Y | +38.20% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $8.18 | |
| SMA 200 | $4.67 | |
| SMA 200 vs Price | -42.86% | |
| SMA 50 | $7.52 | |
| SMA 50 vs Price | -8.05% | |
| Beta | 1.76 | |
| ATR | $0.47 | |
| 14-Day RSI | 53.47 | |
| 10-Day Volatility | 45.76% | |
| 1-Year Volatility | 76.78% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $10.01M | |
| EPS | -$2.36 | |
| Gross Profit | $4.54M | |
| Gross Margin | 45.40% | |
| Operating Profit | -$385.67M | |
| Operating Margin | -3,854.04% | |
| Net Income | -$337.71M | |
| Net Margin | -3,374.72% | |
| EBITDA | -$380.21M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.06 | |
| Current Ratio | 15.95 | |
| Quick Ratio | 15.95 | |
| - | ||
| F-Score | - | |
| Altman Z-Score | 5.90 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 169.67 | |
| PB Ratio | 2.33 | |
| EV/EBITDA | -2.65 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $777.79M | |
| Cash & Equivalents | $124.29M | |
| Total Assets | $871.30M | |
| Current Assets | $809.20M | |
| Total Liabilities | $93.50M | |
| Current Liabilities | $50.73M | |
| Total Debt | $48.50M | |
| Short Term Debt | $5.73M | |
| Accounts Payable | $14.10M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $395.68M | |
| Operating Expenses | $395.68M | |
| Cost Of Goods Sold | $5.46M | |
| SG&A | $76.59M | |
| D&A | $5.46M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$249.11M | |
| CFI | -$41.08M | |
| CFF | $270.15M | |
| Capex | $2.02M | |
| Free Cash Flow | -$251.13M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| Wells Fargo | → | |
| HC Wainwright & Co. | → | |
| Raymond James | → | |
| Guggenheim | → | |
| Wells Fargo | ||
| HC Wainwright & Co. | → | |
| Stifel | → | |
| Goldman Sachs | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with RLAY
Data Sources & References
- RLAY Official Website www.relaytx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1812364/000119312525269601/0001193125-25-269601-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1812364/000095017025027756/0000950170-25-027756-index.htm
- RLAY Profile on Yahoo Finance finance.yahoo.com/quote/RLAY
- RLAY Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rlay
FAQ
What is the ticker symbol for Relay Therapeutics, Inc.?
The ticker symbol for Relay Therapeutics, Inc. is NASDAQ:RLAY
Does Relay Therapeutics, Inc. pay dividends?
No, Relay Therapeutics, Inc. does not pay dividends
What sector is Relay Therapeutics, Inc. in?
Relay Therapeutics, Inc. is in the Healthcare sector
What industry is Relay Therapeutics, Inc. in?
Relay Therapeutics, Inc. is in the Biotechnology industry
What country is Relay Therapeutics, Inc. based in?
Relay Therapeutics, Inc. is headquartered in United States
When did Relay Therapeutics, Inc. go public?
Relay Therapeutics, Inc. initial public offering (IPO) was on July 16, 2020
Is Relay Therapeutics, Inc. in the S&P 500?
No, Relay Therapeutics, Inc. is not included in the S&P 500 index
Is Relay Therapeutics, Inc. in the NASDAQ 100?
No, Relay Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Relay Therapeutics, Inc. in the Dow Jones?
No, Relay Therapeutics, Inc. is not included in the Dow Jones index
When was Relay Therapeutics, Inc. last earnings report?
Relay Therapeutics, Inc.'s most recent earnings report was on November 6, 2025
When does Relay Therapeutics, Inc. report earnings?
The next expected earnings date for Relay Therapeutics, Inc. is February 25, 2026